O repórter gaúcho Pedro Nakamura, do site Matinal, do Rio Grande do Sul, virou alvo de ameaças feitas pelo médico Ricardo Ariel Zimerman, após ter revelado em uma reportagem na terça-feira (24) o uso irregular do medicamento proxalutamida em uma paciente …
La Guarantee Soy Yo – Basic Science – KSU | The Sentinel Newspaper ksusentinel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ksusentinel.com Daily Mail and Mail on Sunday newspapers.
Chinese firmâs COVID-19 drug claims draw scientistsâ skepticism By Syndicated Content
By Gabriel Stargardter
(Reuters) â Chinese biotech firm Kintor Pharmaceutical Limited [9939.HK] saw its stock price jump by more than 20% the day after it announced on April 25 that it had âcompleted the first patient enrollment and dosingâ in a late-stage U.S. clinical trial of its experimental COVID-19 treatment.
It was the companyâs latest announcement about the progress of the drug, Proxalutamide. The Hong Kong-listed companyâs stock price has nearly quadrupled since March 1 as some analysts wrote about the big sales potential for a COVID-19 treatment. Kintor has seen its market capitalization soar to HK$23.4 billion ($3 billion) from HK$6.6 billion ($850 million) on March 1.
Scientists skeptical over Chinese firm s Covid-19 drug claims, firm s stocks surge Reuters Chinese Covid drug
Chinese biotech firm Kintor Pharmaceutical Limited saw its stock price jump by more than 20% the day after it announced on April 25 that it had completed the first patient enrollment and dosing in a late-stage U.S. clinical trial of its experimental COVID-19 treatment.
It was the company s latest announcement about the progress of the drug, Proxalutamide. The Hong Kong-listed company s stock price has nearly quadrupled since March 1 as some analysts wrote about the big sales potential for a COVID-19 treatment. Kintor has seen its market capitalization soar to HK$23.4 billion ($3 billion) from HK$6.6 billion ($850 million) on March 1.
Chinese biotech firm Kintor Pharmaceutical Limited saw its stock price jump by more than 20% the day after it announced on April 25 that it had "completed the first patient enrollment and dosing" in a late-stage U.S. clinical trial of its experimental COVID-19 treatment.